EMPAGLIFLOZIN USE AND THE RISK OF NEPHROLITHIASIS IN PATIENTS WITH TYPE 2 DIABETES

被引：0

作者：

Tang, Francesca ^{[1
]}

Paik, Julie ^{[2
,3
]}

Tesfaye, Helen ^{[2
,3
]}

Zakoul, Heidi ^{[2
,3
]}

Schmedt, Niklas ^{[5
]}

Koeneman, Lisette ^{[6
]}

Seman, Leo ^{[7
]}

Curhan, Gary C. ^{[2
,3
]}

Wexler, Deborah J. ^{[3
,4
]}

Patorno, Elisabetta ^{[2
,3
]}

机构：

[1] Boehringer Ingelheim Pty Ltd, N Ryde, Australia

[2] Brigham & Womens Hosp, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Massachusetts Gen Hosp, Boston, MA USA

[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[6] Lilly Deutschland GmbH, Bad Homburg, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

来源：

NEPHROLOGY | 2023年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：29 / 29

页数：1

共 50 条

[31] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
John E. Anderson
Eugene E. Wright
Charles F. Shaefer
Diabetes Therapy, 2017, 8 : 33 - 53
[32] Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
Lai, Lee-Lee
Vethakkan, Shireene Ratna
Nik Mustapha, Nik Raihan
Mahadeva, Sanjiv
Chan, Wah-Kheong
DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (02) : 623 - 631
[33] Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
Reppo, Ingrid
Jakobson, Maili
Volke, Vallo
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
[34] Empagliflozin monotherapy in drug-naive patients with Type 2 diabetes
Roden, M.
Weng, J.
Merker, L.
Christiansen, A. Vedel
Roux, F.
Salsali, A.
Kim, G.
Stella, P.
Woerle, H. J.
Broedl, U. C.
DIABETIC MEDICINE, 2015, 32 : 89 - 89
[35] Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, Ilkka
Narko, Kirsi
Zeller, Cordula
Green, Alexandra
Salsali, Afshin
Broedl, Uli C.
Woerle, Hans J.
DIABETES CARE, 2015, 38 (03) : 420 - 428
[36] Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
Lee-Lee Lai
Shireene Ratna Vethakkan
Nik Raihan Nik Mustapha
Sanjiv Mahadeva
Wah-Kheong Chan
Digestive Diseases and Sciences, 2020, 65 : 623 - 631
[37] EMPAGLIFLOZIN: A NEW TREATMENT OPTION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS
Dailey, G. E.
DRUGS OF TODAY, 2015, 51 (09) : 519 - 535
[38] Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Esther S. Kim
Emma D. Deeks
Drugs, 2015, 75 : 1547 - 1557
[39] Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1484): : 172 - 174
[40] Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Kim, Esther S.
Deeks, Emma D.
DRUGS, 2015, 75 (13) : 1547 - 1557

← 1 2 3 4 5 →